Repare Therapeutics Signs Exclusive Global License Deal with Debiopharm for Lunresertib

Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Swiss biopharmaceutical company Debiopharm International for lunresertib, a first-in-class precision oncology drug targeting PKMYT1. Lunresertib has shown promising results in clinical trials for difficult-to-treat solid tumors.

Under the deal, Repare will receive a $10 million upfront payment and is eligible for up to $257 million in potential milestone payments, along with royalties on global sales. Debiopharm will take over sponsorship of ongoing and future development activities for lunresertib, including the MYTHIC clinical study.

Steve Forte, CEO of Repare, highlighted that the agreement builds on their existing collaboration with Debiopharm, which is exploring lunresertib in combination with Debio 0123, a brain-penetrant WEE1 inhibitor. Debiopharm’s CEO Bertrand Ducrey emphasized the synergy between the two drugs and their potential to deliver rapid tumor regression in hard-to-treat cancers.

Repare continues to focus on its clinical pipeline, with Phase 1 trial results for its RP-1664 PLK4 inhibitor and RP-3467 Polθ ATPase inhibitor expected in the latter half of 2025.